- Departments, Labs and Institutes
- Research Centers and Programs
- Cancer Risks and Outcomes Program
The goal of the Cancer Risks and Outcomes (CRO) Program is to disentangle the roles of various factors that inform risk, enable early detection and promote optimization of strategies for improved care delivery and outcomes.
The goal of the Cancer Risks and Outcomes (CRO) Program is to disentangle the roles of various factors that inform risk, enable early detection and promote optimization of strategies for improved care delivery and outcomes.
The three aims of the CRO program
The observational discoveries made by CRO members inform the Interventional Cancer Prevention (ICP) and other programs’ intervention research, as well as the Community Outreach and Engagement (COE) component’s evidence-based cancer control activities. The program aims to reduce cancer burden and improve quality and quantity of life in patients and survivors through innovative computation, genomics and real-world evidence.
Aim 1
Etiology
Discover genomic, environmental and modificable risk factors for cancer initiation
Aim 2
Early Detection
Perform biomarker discovery for personalized risk assessment and early detection
Aim 3
Outcomes
Identify the impact of genetics, care delivery and health policy on patient outcomes
Leadership
Paul Scheet, Ph.D.
CRO Co-leader
Sharon Giordano, M.D.
CRO Co-leader
Nika Fedirko, Ph.D.
CRO Associate Leader
Maria Suarez-Almazor, M.D., Ph.D.
CRO Cancer Research Training and Education Coordination Liaison
Alejandro Rauh-Hain, M.D., M.P.H.
CRO Community Outreach and Engagement Liaison
CRO members regularly participate in the following activities
-
CCSG Prevention and Population Sciences Programs Retreat (CRO & ICP)
-
Epidemiology Seminar Series
-
Health Services Research Seminars
Featured Publications
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
The New England Journal of Medicine, 2020
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Science, 2021
Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang LITM, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA
Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment
Journal of Clinical Oncology, 2022
Fahrmann JF, Marsh T, Irajizad E, Patel N, Murage E, Vykoukal J, Dennison JB, Do KA, Ostrin E, Spitz MR, Lam S, Shete S, Meza R, Tammemägi MC, Feng Z, Hanash SM
CCSG Research Programs
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.